APP/tau/alpha-synuclein/TDP-43 (translation)

Class

Translation inhibitor of neurotoxic-protein synthesis

This mechanism targets the production, rather than the clearance, of several proteins whose misfolding and accumulation drive neurodegenerative disease: amyloid precursor protein (APP), tau, alpha-synuclein, and TDP-43. In Alzheimer's disease, APP is cleaved to generate amyloid-beta, and tau forms neurofibrillary tangles; in Parkinson's disease and related synucleinopathies, alpha-synuclein aggregates into Lewy bodies; in amyotrophic lateral sclerosis and frontotemporal dementia, TDP-43 mislocalizes and aggregates. Rather than acting after these proteins are made and have begun to misfold, a translation inhibitor reduces the rate at which ribosomes synthesize them in the first place, lowering the total pool available for pathological aggregation. This strategy is attractive because it addresses a shared upstream step across several distinct proteinopathies, rather than requiring a separate approach for each aggregating protein. The biological rationale rests on regulatory sequences within the messenger RNA of these genes that control how efficiently they are translated, offering a point of pharmacological intervention distinct from gene transcription or protein degradation. Because all four proteins retain necessary physiological roles in healthy neurons, the central challenge for this class of mechanism is achieving a reduction in pathological accumulation without excessively suppressing normal protein function.